PhD Scientific Days 2025

Conservative Medicine I.

A novel treatment of fulminant Clostridioides difficile infection in adult hematological patients during chemotherapy-induced aplasia using pathogen-reduced stool supernatant transplantation

Előadó neve

Dr. Korózs Dorina

Neptun code

Z1KOQ7

Előadó munkahelye

Semmelweis University, Doctoral School of Clinical Medicine, DPC-OHII

Előadó telefonszáma

+36205688766

Előadó e-mail címe

korozs.dorina@gmail.com

Az előadás címe

A novel treatment of fulminant Clostridioides difficile infection in adult hematological patients during chemotherapy-induced aplasia using pathogen-reduced stool supernatant transplantation

Szerző(k) neve és munkahelye

Dr. Korózs Dorina¹, Dr. Szabó Bálint Gergely PhD²

1: Semmelweis University, Doctoral School of Clinical Medicine, DPC-OHII
2: Semmelweis University, Doctoral School of Clinical Medicine, DPC-OHII, Semmelweis University, Department of Haematology and Internal Medicine, Division of Infectology

Bemutatás módja

Szóbeli

Szekció

Conservative Medicine I.

Language of the presentation

Hungarian

Preferred session

Conservative Medicine

Összefoglaló szövege

Introduction
Literature on fecal microbiota transplantation for fulminant Clostridioides difficile infection (CDI) in adults with hematologic malignancies and chemotherapy-induced aplasia remains limited.
Aims
This study aimed to evaluate the safety and efficacy of pathogen-reduced stool supernatant transplantation in this high-risk population.
Methods
A single-center, non-randomized, single-arm interventional study was conducted in 2024. Recipients with fulminant CDI refractory to high-dose oral vancomycin, intravenous metronidazole, and tigecycline were enrolled during chemotherapy-induced aplasia. CDI severity and classification followed current international guidelines. The intervention consisted of two doses of pathogen-reduced stool supernatant administered via nasogastric tube. The fecal material was derived from an unrelated donor and processed through sieve filtration, centrifugation, and mechanical bacterial filtration to achieve pathogen reduction. Quality control was performed using culture-based methods. Clinical, laboratory, radiological parameters were monitored according to a predefined protocol. The primary outcome was sustained clinical cure; secondary outcomes included survival and the incidence of adverse events at +14 and +30 days post-intervention.
Results
Three adult patients with adverse-risk acute myeloid leukemia, representing various treatment stages and remission statuses, received stool supernatant a median of 8 days following CDI onset. By day +14, all patients achieved sustained cure. At day +30, one patient had succumbed to sepsis unrelated to the intervention, while the remaining two maintained remission. No adverse events directly attributable to the intervention were observed, and follow-up laboratory and imaging studies confirmed resolution of CDI.
Conclusion
In this pilot evaluation, pathogen-reduced stool supernatant transplantation appeared to be a safe and potentially effective treatment option for fulminant CDI in adult patients with hematologic malignancies during chemotherapy-induced aplasia.
Funding
DK received the State PhD Scholarship of Hungary. BGSz received the János Bolyai Research Scholarship of the Hungarian Academy of Sciences (BO/00105/23/5) and a Research Grant of the "OTKA" Postdoctoral Excellence Programme 2023 of the National Research, Development and Innovation Office of Hungary (PD-147276).

University

Semmelweis University

Supervisor

Dr. Szabó Bálint Gergely PhD

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

in doctoral studies before complex exam (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

szóbeli

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

9134

Start

12:00

End

12:15